公开(公告)号：US20240368297A1

公开(公告)日：2024-11-07

申请号：US18633939

申请日：2024-04-12

Applicant: Genmab A/S

Inventor： Tommy R. LI ,  Craig J. THALHAUSER

IPC: C07K16/28 ,  A61K31/138 ,  A61K31/573 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).

公开(公告)号：US20230227570A1

公开(公告)日：2023-07-20

申请号：US17923317

申请日：2021-05-07

Applicant: GENMAB A/S

Inventor： Tahamtan AHMADI ,  Manish GUPTA ,  Tommy R. LI ,  Roberto OLIVERI ,  Dena DEMARCO ,  Ida HIEMSTRA ,  Christopher CHIU ,  Brian ELLIOTT ,  Ada AZARYAN

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2887 ,  C07K16/2809 ,  A61P35/00 ,  C07K2317/31 ,  A61K39/00

Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).